Navigation Links
$1.6 Million Agreement to Accelerate Fragile X Research, Inspire Hope

WALNUT CREEK, Calif., Sept. 11 /PRNewswire/ -- A project to advance research and improve treatments for fragile X syndrome will be funded by a new $1.6 million, three-year cooperative agreement with the Center for Disease Control (CDC) and others.

The agreement, intended to bring better care to the more than 100,000 affected Americans, is between The National Fragile X Foundation (NFXF), the CDC's National Center on Birth Defects and Developmental Disabilities, the Association of University Centers on Disabilities, the New York State Institute for Basic Research in Developmental Disabilities and the Data Coordinating Center at Columbia University.

Fragile X syndrome is the most common known cause of inherited intellectual disability and the most common known single gene cause of autism.

The effort will advance the core activities of the Fragile X Clinical and Research Consortium (FXCRC). The NFXF initiated the FXCRC in 2006 to advance clinical practice and facilitate coordinated, collaborative multi-site research. The FXCRC has been meeting regularly since its inception to address best practices in evaluation and treatment, including pharmacological, therapeutic and educational treatments, strategies for supporting and enhancing clinic work, and research priorities. The NFXF prioritized its support of a clinics consortium when it realized the body of Fragile X expertise was scattered throughout North America and organizing that expertise would enhance existing and future research efforts while simultaneously making clinical evaluation and treatment more easily accessible to families.

"The fact the consortium has moved from concept to reality to government funding so quickly is a testament to the organization, its leadership and the families that each year travel to Washington, D.C., to urge Congress to support this important cause," said Jeffrey Cohen, chair, NFXF Public Policy Committee, and father of a son and daughter with fragile X syndrome.

The FXCRC will also address other related conditions such as fragile X-associated tremor/ataxia syndrome and fragile X-associated primary ovarian insufficiency which potentially impact over one million adult male and female carriers in the U.S.

SOURCE The National Fragile X Foundation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Signalife Announces Reverse Stock Split, Preferred Stock Dividend and $5 Million Investment
2. Yongye Biotechnology International Raises $9.4 Million in Private Placement
3. ThermoGenesis Reports Record Quarterly Revenues of $7.2 Million; Full Year Revenues Increase 31 Percent
4. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
5. Vermillion and Stanford Scientists Receive Best Research Award From the PAD Coalition
6. Proteolix Raises $79 Million in Series C Financing
7. Neptune Technologies successfully completes up to $8.5 million debt financing with Desjardins Group
8. Osprey Pharmaceuticals U.S.A., Inc. Completes $11 Million Initial Private Financing
9. Moffitt Cancer Center Receives Prestigious SPORE Grant Worth More Than $10 Million
10. Indevus Announces Private Placement of $105 Million of Non-Recourse Notes
11. TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm
Post Your Comments:
(Date:11/27/2015)... 2015 --> ... companion diagnostics is one of the major ... pharmaceutical companies and diagnostic manufacturers working together ... . --> ... global cancer biomarkers market spread across 89 ...
(Date:11/25/2015)... 2015 --> ... - 2020 report analyzes that automating biobanking workflow ... in long-term samples, minimizing manual errors, improving the ... manual errors such as mislabeling or inaccurate sample ... plays a vital role in blood fractionation, DNA ...
(Date:11/25/2015)... , November 25, 2015 ... cat and human plaque and pave the way for more ... problems in cats     --> ... most commonly diagnosed health problems in cats, yet relatively little ... now. Two collaborative studies have been conducted by researchers from ...
(Date:11/25/2015)... CITY , Nov. 25, 2015 /PRNewswire/ - Aeterna ... affirms that its business and prospects remain fundamentally ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation ... to completion following review of the final interim ... Phase 2 Primary Endpoint in men with heavily ...
Breaking Biology Technology:
(Date:11/4/2015)... , November 4, 2015 ... new market report published by Transparency Market Research "Home Security ... Trends and Forecast 2015 - 2022", the global home security ... 30.3 bn by 2022. The market is estimated to ... period from 2015 to 2022. Rising security needs among ...
(Date:10/29/2015)... 2015  Rubicon Genomics, Inc., today announced an ... its DNA library preparation products, including the ThruPLEX ... Plasma-seq kit. ThruPLEX Plasma-seq has been optimized for ... libraries for liquid biopsies--the analysis of cell-free circulating ... in cancer and other conditions. Eurofins Scientific is ...
(Date:10/27/2015)... Germany , October 27, 2015 ... SMI,s Automated Semantic Gaze Mapping technology (ASGM) automatically maps ... SMI,s Eye Tracking Glasses , so that they ... BeGaze. --> Munich, Germany , ... (ASGM) automatically maps data from mobile eye tracking videos ...
Breaking Biology News(10 mins):